Investing.com - Bristol-Myers Squibb (NYSE: BMY) reported third quarter EPS of $1.80, $0.30 better than the analyst estimate of $1.50. Revenue for the quarter came in at $11.9B versus the consensus estimate of $11.26B.
Guidance
Bristol-Myers Squibb sees FY 2024 EPS of $0.75-$0.95 versus the analyst consensus of $0.71.
Bristol-Myers Squibb's stock price closed at $52.66. It is up 7.98% in the last 3 months and up 2.69% in the last 12 months.
Bristol-Myers Squibb saw 1 positive EPS revisions and 17 negative EPS revisions in the last 90 days. See Bristol-Myers Squibb's stock price’s past reactions to earnings here.
According to InvestingPro, Bristol-Myers Squibb's Financial Health score is "good performance".
Check out Bristol-Myers Squibb's recent earnings performance, and Bristol-Myers Squibb's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar